EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Healthcare Services Group, Inc.
HCSG

HCSG Healthcare Services Group, Inc.

Healthcare Services Group, Inc. · NASDAQ
Market Closed
21.98
▲ ⁦+0.64%⁩ (+0.14)
Market Cap$1.5B
Beta0.82
52w Low52w High
15.1325.75
Last Week
⁦+0.73%⁩
Last Month
⁦-1.12%⁩
Last 3 Months
⁦+10.23%⁩
Last Year
⁦+40.27%⁩
EL7 Factor Analysis
How we score this
Overall93
Excellent — top fifth of the marketSuper StockF 7/9SafeBetter than 93% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
80
12.9x▲17.8xTop tier
▸
Growth
66
5.2%▼7.1%Around median
▸
Quality
72
18.7%▲4.5%Top tier
▸
Safety
88
—2.6xTop tier
▸
Capital Return
68
—2.12%Top tier
▸
Momentum
67
41.5%▲2.9%Top tier
▸
Sentiment
40
5▲3Bottom tier
Fair Value
Low confidenceCurrent price$22
Analyst target · 1 analysts
$26
⁦+18%⁩
See it undervalued
Range ⁦$24–$30⁩
vs
DCF (estimate)
$41
⁦+86%⁩
Sees it clearly undervalued
⁦8.0⁩% discount · ⁦2⁩% growth
Bottom lineThe two methods broadly agree — estimate range ⁦$26–$41⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 1 analysts setting price target
$26.50
⁦+20.6%⁩
Current Price $21.98·Median $26.00
Low
$24.00
High
$30.00
Current price
$21.98
Average target
$26.50
Street summary

Consensus target rises as coverage breadth declines

Bullish tilt

The consensus price target rose to 26.5 from 25.25 over the last 30 days, an increase of 1.25 or 4.95%, while remaining unchanged over the last 7 days. The current price is 21.84, and the consensus target is above it, but current coverage is limited to a single analyst, with a target range of 24 to 30, which limits the significance of the consensus and keeps the dispersion score relatively high.

As of 2026-09-10
Revisions momentum · 30d
⁦+1.9%⁩
Average rating
★ 3.57
Buy
Analyst coverage
7
Buy conviction
57%
Mixed
Rating activity · 30d
0↑ · 0↓
Target dispersion
27%
Analyst ratings over time7 analysts rating
4
3
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.50 → 3.57
Recent analyst moves
  • = Reiterate2026-08-19
    Oppenheimer
    Outperform
  • = Reiterate2026-07-08
    UBS
    Buy
  • = Reiterate2026-04-23
    UBS
    Buy· $27.00
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    12.85x
    3.94x44.30x
    Cheap
  • Forward P/E
    18.00x
    4.64x37.16x
    Cheap
  • EV / EBITDA
    9.49x
    3.77x30.13x
    Very cheap
  • FCF Yield
    9.8%
    -138.2%7.8%
    Exceptional
  • Revenue Growth YoY
    5.2%
    -56.9%93.8%
    Near median
  • EPS Growth YoY
    1215.4%
    -160.1%130.2%
    Exceptional
  • Gross Margin
    17.1%
    12.8%90.7%
    Weak
  • ROIC
    18.7%
    -155.3%16.0%
    Exceptional
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    6.89
    -38.7417.53
    Strong
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-07-22 data

Company Overview

Healthcare Services Group provides contracted operational services to the long-term and post-acute care sector, with its business concentrated in the environmental services and dietary services segments. It also operates a higher education business through Campus Services Group for environmental services and Meriwether Godsey for food services; the higher education business exceeded $100 million in revenue in fiscal 2025, but remained below 10% of the company’s total revenue. Contract economics are protected through field execution and centralized purchasing, with contractual rights allowing increases in food and labor costs to be passed on to customers.

In Q2 fiscal 2026, revenue was $470.8 million and gross profit was $74.8 million, representing a gross margin of approximately 15.9%, while net income was $22.7 million and diluted earnings per share were $0.32. Operating cash flow was $21.9 million, or $27.9 million after excluding the impact of lower accrued payroll. By comparison, the company recorded revenue of $462.8 million, net income of $26.1 million, and earnings per share of $0.37 in Q1 fiscal 2026.

Dietary services represented the largest portion of the Q2 fiscal 2026 mix, with revenue of $257.6 million, or approximately 54.7% of the total, and a segment margin of 7.5%. Environmental services generated revenue of $213.2 million, or approximately 45.3% of the total, and a higher segment margin of 13.3%. Cost of services was $396 million, or 84.1% of revenue, benefiting from strong execution and bad debt expense below its historical average.

What's Driving the Stock

  • Management reaffirmed its expectation for mid-single-digit revenue growth in fiscal 2026 and set a Q3 fiscal 2026 revenue range of $475 million to $485 million, compared with $470.8 million in Q2 fiscal 2026.
Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

Dietary services represent an expansion opportunity within the environmental services customer base, as their penetration is only approximately 50% of that base in the long-term and post-acute care market, while a dietary services account typically generates approximately twice the revenue of an environmental services account at the same facility.
  • The company retains more than 90% of its core business, while management described the new-business pipeline as strong, growing, and distributed roughly evenly between environmental services and dietary services; converting these opportunities into revenue depends on manager availability and customer start dates.
  • The company ended Q2 fiscal 2026 with $200.9 million in cash and marketable securities, along with a $300 million credit facility that was undrawn except for letters of credit, supporting organic growth, acquisitions, and share repurchases.
  • In Q2 fiscal 2026, the company completed a small strategic acquisition within its higher education business and reported that its acquisition pipeline was larger than it had been 6, 12, and 18 months earlier. However, it described the transaction’s revenue contribution during the quarter and subsequent periods as immaterial, making its impact more strategic than an immediate boost to revenue.
  • The company repurchased $20.9 million of shares in Q2 fiscal 2026, bringing the total since the beginning of fiscal 2026 to $44.9 million, under a plan announced in February 2026 targeting $75 million over 12 months.
  • Buying & Selling Case

    ▲ Buying Case4 pts

    • +The HCSG model combines retention of more than 90% of core business with a growing sales pipeline and a clear cross-selling opportunity, because dietary services have penetrated only approximately half of the environmental services customer base even though a dietary account typically generates twice the revenue of an environmental services account at the same facility.
    • +Q2 fiscal 2026 results demonstrated strong operational performance, as cost of services declined to 84.1% of revenue compared with a management target of approximately 86%, and the company recorded net income of $22.7 million and operating cash flow adjusted for the impact of accrued payroll of $27.9 million.
    • +Liquidity of $200.9 million and an undrawn $300 million credit facility provide flexibility to fund organic growth, acquisitions, and share repurchases in parallel, and the company used $44.9 million to repurchase shares during the first half of fiscal 2026.
    • +End demand is tied to the long-term and post-acute care sector; according to management, members of the baby boomer generation begin turning 80 in 2026, and more than 70 million of them will be over age 65 by 2030, supporting expansion of the potential user base for HCSG customers’ services.

    ▼ Selling Case6 pts

    • −Achieving the mid-single-digit growth outlook for fiscal 2026 requires greater acceleration in Q4 fiscal 2026 following the Q3 revenue range of $475 million to $485 million. Management acknowledged that the timing of manager availability and customer start dates could bring opportunities forward or delay them between quarters, so execution of the targeted increase remains exposed to timing risks even with signed contracts and a strong opportunity pipeline.
    • −The Q2 fiscal 2026 margin benefited from factors that may not continue at the same level; bad debt was $4.3 million and remained below 1% of revenue for the second consecutive quarter, compared with a historical average of between 1% and 1.5%. The benefit from self-insurance reserve adjustments also declined to $1.3 million from more than $4.5 million in Q1 fiscal 2026, and management expects this benefit to trend toward zero over time, which could move cost of services back toward the 86% target.
    • −The Genesis bankruptcy remains a specific credit and operational exposure, although HCSG said on July 22, 2026, that it continued serving the facilities without disruption to operations or payments. In January 2026, the bankruptcy court approved the sale of Genesis to 101 West State Street, and management expected the transaction to close in late Q3 or early Q4 fiscal 2026, making the continuity of service and collections dependent on completion of the process as expected.
    • −At-home food price index inflation rose to 1% in Q2 fiscal 2026 after three consecutive quarterly declines, while management pointed to continued volatility in energy and supply markets due to geopolitical conflicts. HCSG has contractual rights to pass through food and wage inflation and can change supply sources, but broader cost pressures could test the speed of pass-throughs and purchasing efficiency.
    • −The analyst consensus is Neutral, and the target range is relatively wide at $24 to $30, a 25% difference between the endpoints. The average target of $26.5 is only approximately 2.9% above the 52-week range high of $25.75, reflecting a balance between execution opportunities and growth and margin risks rather than a clear consensus on a strong bullish case.

    Valuation

    The analyst consensus rates HCSG as Neutral, with an average target of $26.5 and a range of $24 to $30; the average is approximately 2.9% above the 52-week range high of $25.75, while the highest target is approximately 16.5% above it. The breadth of the targets and the 52-week range of $15.13 to $25.75 indicate that the valuation is sensitive to the success of revenue acceleration in the second half of fiscal 2026, the sustainability of the improvement in cost of services, and the fading of insurance reserve benefits.

    HoldAnalyst target: $26.5(+20.6%)

    Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.

    FAQ

    What is driving HCSG’s growth in fiscal 2026?

    On July 22, 2026, management reaffirmed its expectation for mid-single-digit revenue growth in fiscal 2026 and set Q3 fiscal 2026 revenue at between $475 million and $485 million. Growth depends on developing management candidates, converting the sales pipeline, and retaining more than 90% of core business. Dietary services also represent a cross-selling opportunity because their penetration remains at approximately 50% of the environmental services customer base and because a dietary account typically generates twice the revenue of an environmental services account at the same facility.

    How was HCSG’s revenue distributed in Q2 fiscal 2026?

    Dietary services revenue was $257.6 million with a segment margin of 7.5%, representing approximately 54.7% of the company’s revenue. Environmental services revenue was $213.2 million with a segment margin of 13.3%, representing approximately 45.3% of the total. Accordingly, HCSG’s total revenue reached $470.8 million, with net income of $22.7 million and diluted earnings per share of $0.32.

    Is HCSG’s margin improvement in Q2 fiscal 2026 sustainable?

    Cost of services was $396 million, or 84.1% of revenue, in Q2 fiscal 2026, better than management’s target of approximately 86%. Strong execution and bad debt of $4.3 million, or less than 1% of revenue, contributed to this result. However, the benefit from self-insurance reserves declined to $1.3 million from more than $4.5 million in Q1 fiscal 2026, and management expects that benefit to gradually trend toward zero.

    How large is HCSG’s opportunity in the higher education business?

    The higher education business exceeded the $100 million revenue threshold in fiscal 2025 but remained below 10% of the company’s total revenue. HCSG operates in this market through Campus Services Group for environmental services and Meriwether Godsey for food services, and it seeks to cross-sell the two offerings. The company closed a small acquisition within the business in mid-April 2026, but said its contribution to revenue in Q2 fiscal 2026 and subsequent periods was immaterial.

    What is the impact of the Genesis bankruptcy on HCSG?

    Management said on the July 22, 2026 call that HCSG continued providing services to Genesis facilities without disruption to operations, operating results, or payments. In January 2026, the bankruptcy court approved the sale of Genesis to 101 West State Street, a group of operators with an existing relationship with HCSG. According to management’s estimate on the call, the transaction was moving toward a close in late Q3 or early Q4 fiscal 2026, with service expected to continue without disruption through the sale date.

    How is HCSG using its liquidity in fiscal 2026?

    The company ended Q2 fiscal 2026 with $200.9 million in cash and marketable securities, in addition to a $300 million credit facility that was undrawn except for letters of credit. Management allocates capital among organic growth, acquisitions, and share repurchases, and completed a small higher education acquisition during the quarter. It also repurchased $20.9 million of shares during the quarter, bringing the fiscal 2026 total to $44.9 million under a plan targeting $75 million over 12 months beginning with the February 2026 announcement.

  • −Insider activity recorded one sale and no purchases during the three months ending with the latest transaction on August 4, 2026, for net sales of approximately $362.5 thousand. This remains a weak standalone signal because insider sales may be prearranged, and the available information contains no evidence to the contrary.